Safety and Efficacy Study to Treat Bacterial Vaginosis
A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States
-
-
Arizona
-
Phoenix, Arizona, United States
-
-
California
-
La Mesa, California, United States
-
Los Angeles, California, United States
-
San Diego, California, United States
-
Torrance, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
-
Connecticut
-
Groton, Connecticut, United States
-
-
Florida
-
Boyton Beach, Florida, United States
-
Clearwater, Florida, United States
-
Miami, Florida, United States
-
North Miami, Florida, United States
-
Sunrise, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
Augusta, Georgia, United States
-
Roswell, Georgia, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Louisiana
-
Marrero, Louisiana, United States
-
-
Massachusetts
-
Falls River, Massachusetts, United States
-
-
Michigan
-
Detroit, Michigan, United States
-
Saginaw, Michigan, United States
-
-
Nebraska
-
Lincoln, Nebraska, United States
-
-
New Jersey
-
Lawrenceville, New Jersey, United States
-
Neptune, New Jersey, United States
-
Plainsboro, New Jersey, United States
-
-
Ohio
-
Columbus, Ohio, United States
-
-
Pennsylvania
-
Jenkintown, Pennsylvania, United States
-
Philadelphia, Pennsylvania, United States
-
-
South Carolina
-
Columbia, South Carolina, United States
-
-
Tennessee
-
Jackson, Tennessee, United States
-
-
Texas
-
Corpus Christi, Texas, United States
-
Houston, Texas, United States
-
Schertz, Texas, United States
-
-
Vermont
-
Williston, Vermont, United States
-
-
Virginia
-
Virginia Beach, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
Tacoma, Washington, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have a clinical diagnosis of bacterial vaginosis as determined by the investigator.
- Other items as identified in the protocol.
Exclusion Criteria:
- Have a known or suspected other infectious cause of vulvovaginitis.
- Other items as identified in the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Vehicle
Treatment with the vehicle (placebo)
|
The vehicle vaginal gel in an applicator (placebo).
|
|
Experimental: Product 55394
Treatment with product 55394
|
Product 55394 vaginal gel in a prefilled applicator.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Cure
Time Frame: Day 21
|
The proportion of subjects with a clinical cure at the Day 21 visit, as assessed by the investigator.
|
Day 21
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Therapeutic Cure
Time Frame: Day 21
|
The proportion of subjects with a therapeutic cure at the Day 21 visit.
Therapeutic cure is defined as both a clinical cure and bacteriological cure as assessed by the investigator and the central laboratory, respectively.
|
Day 21
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Ron Staugaard, Medicis Pharmaceutical
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MP-1601-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.